Q4 witnessed significant one offs (M&As, write-offs etc.)- Alembic's Aleor acquisition, Aurobindo's Veritaz acquisition, Biocon's Viatris Biosimilars acquisition, Lupin's Anglo French Drugs CNS & VMS acquisition, Taro's Alchemy acquisition and Sun Pharma's plaintiff settlement. Adjusted PAT is...